drugset / Trial / NCT05914753

Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer

NCT05914753

RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluate the effectiveness of Xihuang Pill in improving the efficacy of neoadjuvant chemotherapy for breast cancer

Timeline

Start
2023-07-01
Primary completion
2024-06-01
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Xihuang Pill Unknown 3 g Oral
Background Cyclophosphamide Other / unclassified 600 mg/m2
Background Docetaxel Small molecule 100 mg/m2
Background Epirubicin Small molecule 90 mg/m2

Indications